All lobbying filings

SOLUGEN INC

SOLUGEN INC filed a Q1 report for SOLUGEN INC on April 18, 2025.

Lobbying for SOLUGEN INC · Industrial Biomanufacturing

All filings by SOLUGEN INC · Everything SOLUGEN INC has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 18, 2025

Expenses

$150,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Texas

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Defense

Support the use of bio-based chemicals in the Department of Defense, generally. (S. 4638) FY 2025 National Defense Authorization Act, educate and advocate for secure supply chains. FY 2026 Defense Appropriations. FY 2026 National Defense Authorization Act.

Environment/Superfund

Educate policymakers about Solugen's technology to produce bio-based chemicals, generally. Monitor implementation of (P.L.117-58), Infrastructure Investment and Jobs Act. Monitor implementation of (P.L. 117-169), Inflation Reduction Act. Monitor implementation of (Executive Order: 14081) Executive Order on Advancing Biotechnology and Biomanufacturing. Educate policymakers on the Premanufacture Notice decision for glucaric acid under (P.L. 114-18) the Frank R. Lautenberg Chemical Safety for the 21st Century Act and on the Environmental Protection Agency's chemical review process.

Bills named in this filing 1

S. 4638
National Defense Authorization Act for Fiscal Year 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.